Pfizer India has become the first pharmaceutical firm to seek an emergency use authorisation for its Covid-19 vaccine in the country after its parent company secured such clearance in the UK and Bahrain.
In its application submitted to the Drugs Controller General of India (DCGI), the firm has sought permission to import the vaccine for sale and distribution in the country, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, official sources told the news agency.
“Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization (EUA) for its COVID-19 vaccine in India,” a source said.
“The firm has submitted the EUA application in Form CT-18 for grant of permission to import and market Pfizer-BioNTech’s COVID-19 mRNA vaccine BNT162b2 in the country,” the source said, citing the application.
V K Paul, who chairs the high-level National Expert Group on Vaccine Administration, had earlier spelt out India’s strategy with respect to candidates like Pfizer and Moderna which have shown positive results in Phase III abroad but are not being tested here.
“We know that doses of this vaccine (Pfizer) will not be available in huge quantities… If this vaccine candidate has to come, and if we require it, we are preparing ourselves… we have parallel plans,” Paul had said.
For the vaccine to be considered for use here, the Indian subsidiary of Pfizer will have to approach the regulator and share the data it has submitted to the UK regulator.
“They can then ask for an approval and, accordingly, the regulator will take a decision,” an official had told The Indian Express.
The UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19, with the UK regulator Medicines and Healthcare products Regulatory Agency (MHRA) granting a temporary authorisation for its emergency use.
The British regulator said the jab, which claims to offer up to 95 per cent protection against COVID-19, is safe for roll-out.
Bahrain on Friday also announced that it has granted a EUA for the two-dose vaccine made by Pfizer and its German partner BioNTech. The pharma company has already applied to the US FDA seeking EUA for the vaccine.
The extremely low temperature of minus 70 degrees Celsius required for storing the vaccine poses a big challenge for its delivery in a country like India, especially in its smaller towns and rural areas where maintaining such cold chain facilities would be very difficult, top government officials have said.
When contacted, Pfizer said it remains committed to engaging with the Government of India and explore opportunities to make this vaccine available for use in the country.
“During this pandemic phase, Pfizer will supply this vaccine only through government contracts based on agreements with respective government authorities and following regulatory authorisation or approval,” the global pharma major said in a statement.
Five vaccines are in advanced phases of clinical trials in India with the Serum Institute of India conducting the phase-3 trial of the Oxford-Astrazeneca COVID-19 vaccine, while the indigenously developed vaccine by Bharat Biotech in collaboration with ICMR has already started the phase-3 clinical trial.
Drug firm Zydus Cadila has received the approval from the DCGI to start the phase-3 clinical trials of the indigenously-developed anti-coronavirus vaccine.
Dr Reddy’s Laboratories and the Russian Direct Investment Fund (RDIF) have announced that they commenced adaptive phase 2 and 3 clinical trials for COVID-19 vaccine Sputnik V in India, Also, Biological E. Ltd has started early phase 1 and 2 human trials of its Covid-19 vaccine candidate.
With inputs from PTI and The Indian Express